<DOC>
	<DOCNO>NCT00004650</DOCNO>
	<brief_summary>OBJECTIVES : I . Quantify periodontal alveolar bone loss rate postmenopausal woman . II . Evaluate effect estrogen alveolar bone loss rate patient . III . Determine whether change periodontal bone mass relate bone mass change skeletal sit patient .</brief_summary>
	<brief_title>Phase III Randomized Study Effect Postmenopausal Estrogen Replacement Therapy Alveolar Bone Loss</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double-blind , placebo control study . Patients randomly assign receive placebo conjugate estrogen , prior hysterectomy , medroxyprogesterone . Patients also receive calcium supplementation therapy daily 3 year . Participants placebo group may remove study bone loss exceed 5 % per year . A study duration 3 year anticipate .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Women postmenopausal least 2 year At least 10 teeth radiographic measurement obtain , i.e . : Not severely tilt Not closely space interproximal bone thin Not position restrict access</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 1999</verification_date>
	<keyword>disease-related problem/condition</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>rare disease</keyword>
</DOC>